Dallas, Texas 04/23/2014 (FINANCIALSTRENDS) – IsoRay, Inc. (NYSEMKT:ISR) for perhaps the first time this year, posting substantial gains of 0.42$, arriving close to $2.40 per stock. The company has been posting results of its first prostate cancer implant – which is combining IsoRay’sCesium 131 seeds with C4 Imaging Sirius positive signal MRI markers.
IsoRay, Inc. (NYSEMKT:ISR) CEO Dwight Babcock reported that, “We are very excited to have our Cesium-131 isotope seeds selected to partner with C4 Imaging’s innovative positive signal MRI markers in the treatment of prostate cancer.”
IsoRay, Inc. (NYSEMKT:ISR) has reported that the stock prices of this company are in the infra-day trading stock range of $2.23 and $2.40. The 52-week trading price is low at $0.44 and $3.77 high.
IsoRay, Inc. (NYSEMKT:ISR) EPS is -0.13, the stock has outstanding shares of 53.99 million. Beta is 0.34. The market cap for this stock is currently at 123.10 million.
IsoRay, Inc.(NYSEMKT:ISR) offers a wide-range of isotope-based medical products as well as devices, These are typically used in treating cancer as well as a range of other diseases.
IsoRay, Inc. (NYSEMKT:ISR) has received FDA approval for treating prostate cancer as well as a range of other ocular melanoma and various other types of cancers. the key product in use to treat the cancers is the Cesium 131. These applications are useful in treating tumors which are radio sensitive.
The company has been building cancer solutions, in the past few years seeking solutions which will offer effective solutions.
The company has been successful in receiving regulatory approval for the sale of CS131 seeds in Russia.
Now, with the implant results proving to be a success, ISR will now see some action on the stock front and financial fronts as well. Of the several stock participants in the prostate cancer condition, ISR is expected to see results of success.